Revvity, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023
February 01, 2024 at 06:00 am EST
Share
Revvity, Inc. reported earnings results for the fourth quarter and full year ended December 31, 2023. For the fourth quarter, the company reported sales was USD 695.9 million compared to USD 741.21 million a year ago. Net income was USD 78.56 million compared to USD 127.66 million a year ago. Diluted earnings per share from continuing operations was USD 0.52 compared to USD 0.77 a year ago. Diluted earnings per share was USD 0.64 compared to USD 1.01 a year ago.
For the full year, sales was USD 2,750.57 million compared to USD 3,311.82 million a year ago. Net income was USD 693.09 million compared to USD 569.18 million a year ago. Diluted earnings per share from continuing operations was USD 1.44 compared to USD 4.06 a year ago. Diluted earnings per share was USD 5.55 compared to USD 4.5 a year ago.
Revvity, Inc. (formerly PerkinElmer, Inc.) specializes in designing, manufacturing, and marketing measurement devices and analytical instruments for the healthcare, environmental, scientific research, industry and food sectors. Net sales (including intragroup) break down by family of products as follows:
- medical diagnosis equipment (61%);
- analytical tools and instruments (39%): biological molecular research tools, thermal analysis software, chemical and environmental measurement tools, genetic screening instruments, reagents, etc.
Net sales are distributed geographically as follows: the United States (46.7%), China (14.4%), the United Kingdom (4.1%) and other (34.8%).
REVVITY, INC. 
